Ireland
--:--IST
Latest
Clinical Trials in France / NCT05787366
Active, not recruiting Not applicable

Effect of a Health Pathway for People With Persistent Symptoms Covid-19

NCT05787366 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-11-15
Last updated
2026-05-06

Condition(s) studied

COVID-19

Investigational drug(s) / intervention(s)

usual care and follow-up by a nursePersonalized Multifactorial Intervention (IMP)

usual care and follow-up by a nurse: follow-up by a nurse and referral to a specialist(s) according to symptoms

Personalized Multifactorial Intervention (IMP): The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops : * Knowledge of the disease and specific management, (led by the nurse) * Covid-19 and anxiety/depression, (psychologist) * Fatigue and adapted physical activities (video capsules) * Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse) * The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential.

Study summary

People with persistent symptoms of covid-19 have increased needs for needs for management of their overall health (physical, psychological and social). Persistent covid-19 symptoms have a negative impact on quality of life. By proposing a follow-up and an intervention on the reduction of these symptoms, the symptoms, the study will improve quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Persons who have been infected with Covid-19. * Person with persistent clinical signs of Covid-19 for more than 12 weeks, referred by one of the partner structures of the project. The persistent signs of Covid-19 are: fatigue which can be severe, neurological disorders neurological disorders (cognitive, sensory, headaches), cardio-thoracic disorders (pain and chest tightness, tachycardia, dyspnea, cough) and disorders of smell and taste. Pain, digestive disorders and skin disorders are also common. * Person who has agreed to participate and has given informed consent to participate in the study Exclusion Criteria: * Refused to participate in the study * Person under legal protection * Person with severe cognitive impairment

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Urps Medecins Libéraux Auvergne-Rhône-Alpes Lyon France
Chu Saint-Etienne Saint-Etienne France
DAC Loire Saint-Etienne France

More Centre Hospitalier Universitaire de Saint Etienne trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05787366 on ClinicalTrials.gov ↗ ← All trials in France